The claim, first, as the vendor states it: a Dublin market-research house, Research and Markets, projects the global CAR T-cell therapy market to nearly double, from $7.24 billion in 2026 to $13.78 billion by 2031, at a compound annual rate of 13.7%. The drivers it names are rising cancer prevalence, technological advances in the engineered-cell treatments, expanding clinical trials and growing investment. The restraints it names, with equal formality, are adverse effects, the high cost of treatment, reimbursement hurdles, surveillance of safety over the long term and labeling standards still evolving. Both halves of that ledger deserve their place in the account.
What the product record shows, on the report’s own numbers: Yescarta, Gilead’s therapy, held the largest product share in 2025, a position built on strong response rates and lasting remissions in relapsed and refractory disease. The pipeline of names around it, Kymriah, Carvykti, Abecma, Tecartus and Breyanzi, targets chiefly CD19 and BCMA across multiple myeloma, B-cell lymphoma and acute lymphoblastic leukemia. Hospitals, not clinics, were the largest end-user segment in 2025 and are expected to keep the fastest growth, for a structural reason: cell therapies demand the trial infrastructure, monitoring and pharmacy collaboration that only large institutions currently hold.
The confirmed caution sits on the label itself. In January 2024, according to Endpoints News, the FDA told Novartis, Gilead, Bristol-Myers Squibb and Johnson & Johnson to add boxed warnings to six CAR-T therapies noting the risk of secondary cancers, the culmination of a safety review. That regulatory fact has not slowed the forecasts, but it is the asterisk every projection carries: the same mechanism that sends cancers into remission is under long-term surveillance for what it might seed. Claim and counterweight, in this field, travel together.
Regionally, the account indicates the center of gravity is shifting east. Asia Pacific is forecast to post the highest regional growth through 2031, on favorable regulatory frameworks, expedited approvals and a deep trial pipeline; in China, collaboration among hospitals, universities and industry, with studies reporting encouraging outcomes in leukemia, lymphoma and even solid tumors, is expected to strengthen the regional position. The report’s own company roster makes the point quietly: alongside the American and Swiss incumbents sit CARsgen, IASO Biotherapeutics and JW Therapeutics of China and ImmunoAct of India.
The frontier the industry now advertises is expansion beyond blood cancers into solid tumors and new disease areas, and a platform shift toward allogeneic CAR-T and CAR-NK designs that could, if they work, broaden access beyond today’s bespoke, patient-by-patient manufacturing. The forecast, it bears saying, is a research house’s arithmetic, sold as a 320-page report to the very companies it profiles. The patients reading only the headlines should hold both numbers at once: a market headed toward $13.78 billion, and a warning label that the treatment for one cancer must itself be watched for causing another.
Sources
- CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
- FDA tells CAR-T makers to add boxed warnings of secondary cancer
